Eventide Asset Management LLC Raises Position in Audentes Therapeutics (BOLD)

Eventide Asset Management LLC increased its position in shares of Audentes Therapeutics (NASDAQ:BOLD) by 20.0% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 270,000 shares of the biotechnology company’s stock after purchasing an additional 45,000 shares during the quarter. Eventide Asset Management LLC owned 0.73% of Audentes Therapeutics worth $8,114,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently modified their holdings of the stock. American International Group Inc. raised its holdings in Audentes Therapeutics by 15.9% during the first quarter. American International Group Inc. now owns 12,829 shares of the biotechnology company’s stock worth $386,000 after purchasing an additional 1,761 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Audentes Therapeutics by 19.5% in the first quarter. The Manufacturers Life Insurance Company now owns 15,630 shares of the biotechnology company’s stock worth $469,000 after acquiring an additional 2,555 shares during the last quarter. Teachers Advisors LLC raised its holdings in shares of Audentes Therapeutics by 12.7% in the fourth quarter. Teachers Advisors LLC now owns 30,347 shares of the biotechnology company’s stock worth $948,000 after acquiring an additional 3,421 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of Audentes Therapeutics by 27.4% in the first quarter. Rhumbline Advisers now owns 17,008 shares of the biotechnology company’s stock worth $511,000 after acquiring an additional 3,657 shares during the last quarter. Finally, Tortoise Investment Management LLC acquired a new position in shares of Audentes Therapeutics in the first quarter worth $112,000. 94.23% of the stock is owned by hedge funds and other institutional investors.

A number of research firms have recently weighed in on BOLD. ValuEngine raised Audentes Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, June 1st. Mizuho reissued a “hold” rating and issued a $38.00 price target on shares of Audentes Therapeutics in a report on Monday, May 21st. Raymond James reissued a “hold” rating on shares of Audentes Therapeutics in a report on Thursday, May 17th. HC Wainwright set a $40.00 price target on Audentes Therapeutics and gave the stock a “buy” rating in a report on Thursday, May 17th. Finally, William Blair reissued a “buy” rating on shares of Audentes Therapeutics in a report on Thursday, May 17th. Three equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $37.22.

Shares of NASDAQ:BOLD opened at $39.07 on Tuesday. Audentes Therapeutics has a 52 week low of $15.74 and a 52 week high of $42.61.

Audentes Therapeutics (NASDAQ:BOLD) last announced its quarterly earnings data on Wednesday, May 9th. The biotechnology company reported ($0.74) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.81) by $0.07. research analysts anticipate that Audentes Therapeutics will post -3.31 EPS for the current fiscal year.

In other news, VP Suyash Prasad sold 1,900 shares of Audentes Therapeutics stock in a transaction on Monday, March 26th. The stock was sold at an average price of $30.00, for a total value of $57,000.00. Following the completion of the sale, the vice president now owns 1,900 shares of the company’s stock, valued at $57,000. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Matthew R. Patterson sold 20,300 shares of Audentes Therapeutics stock in a transaction on Monday, May 21st. The shares were sold at an average price of $38.15, for a total value of $774,445.00. Following the completion of the sale, the chief executive officer now directly owns 13,600 shares of the company’s stock, valued at approximately $518,840. The disclosure for this sale can be found here. In the last ninety days, insiders sold 78,700 shares of company stock valued at $2,473,406. Company insiders own 6.60% of the company’s stock.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Institutional Ownership by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply